Test Predicts Novartis AG's Kinase Inhibitor Resistance in CML, Hokkaido University Study
MedPage Today -- A novel laboratory test may accurately distinguish which chronic myeloid leukemia (CML) patients will develop resistance to imatinib (Gleevec), researchers said.